Results 151 to 160 of about 2,206,905 (180)

Genome Sequencing of Undiagnosed European Patients Suspected of Hereditary Cancer: Diagnostic Yield and Identification of Candidate Causative Variants. [PDF]

JCO Precis Oncol
Martins N, Terradas M, Garcia-Pelaez J, Sommer AK, Demidov G, Matalonga L, Ramos-Muntada M, Te Paske IBAW, Spier I, Mensenkamp A, Schuurs-Hoeijmakers J, Gullo I, São José C, Pedro AM, Gouveia Silva R, Sousa AB, Amoroso Canão P, Fernandes S, Garrido L, Dupont J, Maia S, Sousa G, Irmejs A, Barili V, Blatnik A, Rofes P, Brunet J, Capellá G, Laurie S, Lázaro C, Hoogerbrugge N, de Voer RM, Aretz S, Oliveira C, Valle L.   +34 more
europepmc   +1 more source

The Diagnostic Accuracy of the Second Revision of the European Academy of Neurology/Peripheral Nerve Society Guideline for Diagnosing Chronic Inflammatory Demyelinating Polyradiculoneuropathy. [PDF]

Eur J Neurol
van Doorn IN, Baars AE, Wieske L, Jacobs BC, Kuitwaard K, van der Pol WL, van Doorn PA, van Schaik IN, Eftimov F, Goedee HS, Drenthen J, Verhamme C.   +11 more
europepmc   +1 more source

Early Dose Reduction or Discontinuation vs Maintenance Antipsychotics After First Psychotic Episode Remission: A Randomized Clinical Trial.

JAMA Psychiatry
Sommer IE, de Beer F, Gangadin S, de Haan L, Veling W, van Beveren N, Boonstra N, Rosema BS, van Os J, Kikkert M, Koops S, Noorman J, Thielen F, Wijnen B, Begemann M, HAMLETT-OPHELIA Consortium.   +15 more
europepmc   +1 more source

Personalised approach to hypertension treatment: Rationale and design of the HYPERMARKER randomised trial

Chapman M, Knikman JE, Mobley A, Lagerwaard B, Martinez-Garcia F, Zeitouny S, Engler D, Schnabel RB, Spiering W, Bos ID, Champsi A, Carter AW, Hankemeier T, Grobbee D, Kotecha D, the HYPERMARKER Consortium.   +15 more
europepmc   +1 more source

A double index for assessing symptoms in psychosis based on acoustic and semantic information

Kirdun M, He R, Demirlek C, García-Molina JT, Hüppi R, Surbeck W, Dannecker N, Verim B, Yalincetin B, Ortiz García de la Foz V, Arriola RA, Bora E, Figueroa-Barra AI, Spaniel F, Palaniyappan L, Sommer IE, Homan P, Hinzen W, Palominos C.   +18 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Seismology education and public-outreach resources for a spectrum of audiences, as provided by the IRIS Consortium

The Leading Edge, 2015
Abstract The Incorporated Research Institutions for Seismology's (IRIS) Education and Public Outreach (EPO) program is committed to advancing awareness and understanding of seismology and geophysics while also inspiring careers in the earth sciences.
Michael Hubenthal
exaly   +2 more sources

IRIS—A university consortium for seismology

Reviews of Geophysics, 1987
IRIS is a university consortium organized to provide modernized seismographic networks and data distribution facilities for the university research community and funded by the National Science Foundation (NSF). There are currently 50 member institutions, each of which is represented on the Board of Directors.
exaly   +2 more sources

IRIS: Consortium of Art History and Humanities Libraries in Florence

Art Libraries Journal, 2005
Florence in Italy, a renowned centre for art and culture, has been called a ‘living museum’ of the Italian Renaissance. Today it is also the site of a co-operative international project bringing the world’s scholarly community access to the bibliographic patrimonies of a group of special art and humanities libraries.
Anna Mieli, Margaret D’Ambrosio
openaire   +1 more source

Safety and tolerability of FOLFIRABRAX [5-Fluourouracil (5-FU), irinotecan (IRI), and nab-paclitaxel (NP)] with genotype-guided dosing of IRI in previously untreated advanced gastrointestinal (GI) cancer patients (pts): A multicenter trial of the University of Chicago Personalized Cancer Care Consortium.

Journal of Clinical Oncology, 2018
e16241Background: 5-FU, IRI, and NP are active in GI cancers; the combination, FOLFIRABRAX, has not been evaluated. UGT1A1 clears SN-38, the active metabolite of IRI.
Smita Suhas Joshi, Theodore Karrison, Daniel V.T. Catenacci, Jaclyn D Peterson, Mark Zalupski, Brooke Elizabeth Phillips, Ahad Ali Sadiq, Amikar Sehdev, James Lloyd Wade, Vincent J. Picozzi, Andrea Louise Amico, Robert de Wilton Marsh, Mark Kozloff, Blase N. Polite, Hedy L. Kindler, Manish Sharma   +15 more
openaire   +1 more source

Abstract CT146: Plasma pharmacokinetics of liposomal irinotecan (nal-IRI) in pediatric oncology patients with recurrent or refractory solid tumors: South Plains Oncology Consortium Study 2012-001

Cancer Research, 2017
Abstract Background/Objectives: Children with relapsed or refractory solid tumors have a poor prognosis. Irinotecan is active in some pediatric solid tumors and synergizes with alkylating agents. nal-IRI encapsulates irinotecan into long-circulating, liposome-based nanoparticles.
Paul D. Harker-Murray, William H. Meyer, Patrick Leavey, Min H. Kang, Hwangeui Cho, Bambang S. Adiwijaya, Jonathan B. Fitzgerald, J Marc Pipas, Daryl C. Drummond, C. Patrick Reynolds   +9 more
openaire   +1 more source